SLC7A5 and breast carcinoma: Furthermore, SLC7A5 is a candidate molecular target for cancer therapeutics and inhibition of transport with JPH203 (Nanvuranlat) significantly suppressed the proliferation of estrogen deprivation-resistant (EDR) breast carcinoma cell lines [31].